Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Jackson, Christopher ^a   Ruzevick, Jacob ^a   Phallen, Jillian ^a   Belcaid, Zineb ^a   Lim, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARMUSTINE; CINTREDEKIN BESUDOTOX; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR VIII KEYHOLE LIMPET HEMOCYANIN CONJUGATE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4 PSEUDOMONAS EXOTOXIN FUSION PROTEIN; LOMUSTINE; PROCARBAZINE; RINDOPEPIMUT; STAT3 PROTEIN; TEMOZOLOMIDE; THYMIDINE KINASE; TRABEDERSEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE; WP 1066;

ABSENCE OF SIDE EFFECTS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL TYPE; CHILL; CONFUSION; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; EDEMA; EFFECTOR CELL; FEVER; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LYMPHOCYTOPENIA; LYMPHOKINE ACTIVATED KILLER CELL; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOMNOLENCE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY;

ANIMALS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84855604775     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/732413     Document Type: Review

References (260)

1. Stupp R., Mason W. P., Van Den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma The New England Journal of Medicine 2005 352 10 987 996 (Pubitemid 40349501)
2. Charles N. A., Holland E. C., Gilbertson R., Glass R., Kettenmann H., The brain tumor microenvironment Glia 2011 59 8 1169 1180
3. Phillips H. S., Kharbanda S., Chen R., Forrest W. F., Soriano R. H., Wu T. D., Misra A., Nigro J. M., Colman H., Soroceanu L., Williams P. M., Modrusan Z., Feuerstein B. G., Aldape K., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006 9 3 157 173 (Pubitemid 43357943)
4. Gulley J. L., Drake C. G., Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research Clinical Cancer Research 2011 17 12 3884 3891
5. Cameron F., Whiteside G., Perry C., Ipilimumab: first global approval Drugs 2011 71 8 1093 1104
6. Karan D., Dubey S., Van Veldhuizen P., Holzbeierlein J. M., Tawfik O., Thrasher J. B., Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice Immunotherapy 2011 3 6 735 746
7. Disis M. L., Immunologic biomarkers as correlates of clinical response to cancer immunotherapy Cancer Immunology, Immunotherapy 2011 60 3 433 442
8. Pachter J. S., De Vries H. E., Fabry Z., The blood-brain barrier and its role in immune privilege in the central nervous system Journal of Neuropathology and Experimental Neurology 2003 62 6 593 604 (Pubitemid 36682632)
9. Fabry Z., Raine C. S., Hart M. N., Nervous tissue as an immune compartment: the dialect of the immune response in the CNS Immunology Today 1994 15 5 218 224 (Pubitemid 24137975)
10. Lampson L. A., Hickey W. F., Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from 'histologically normal' to that showing different levels of glial tumor involvement Journal of Immunology 1986 136 11 4054 4062 (Pubitemid 16123050)
11. Wintterle S., Schreiner B., Mitsdoerffer M., Schneider D., Chen L., Meyermann R., Weller M., Wiendl H., Expression of the B7-Related Molecule B7-H1 by Glioma Cells: A Potential Mechanism of Immune Paralysis Cancer Research 2003 63 21 7462 7467 (Pubitemid 37413489)
12. Sloan D. J., Wood M. J., Charlton H. M., The immune response to intracerebral neural grafts Trends in Neurosciences 1991 14 8 341 346
13. Tambur A. R., Transplantation immunology and the central nervous system Neurological Research 2004 26 3 243 255 (Pubitemid 38647178)
14. Yang I., Han S. J., Kaur G., Crane C., Parsa A. T., The role of microglia in central nervous system immunity and glioma immunology Journal of Clinical Neuroscience 2010 17 1 6 10
15. Hussain S. F., Heimberger A. B., Immunotherapy for human glioma: Innovative approaches and recent results Expert Review of Anticancer Therapy 2005 5 5 777 790 (Pubitemid 41599954)
16. Serot J. M., Foliguet B., Béné M. C., Faure G. C., Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium NeuroReport 1997 8 8 1995 1998 (Pubitemid 27314323)
17. Goldmann J., Kwidzinski E., Brandt C., Mahlo J., Richter D., Bechmann I., T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa Journal of Leukocyte Biology 2006 80 4 797 801 (Pubitemid 44835898)
18. Weller R. O., Engelhardt B., Phillips M. J., Lymphocyte targeting of the central nervous system: A review of afferent and efferent CNS-immune pathways Brain Pathology 1996 6 3 275 288 (Pubitemid 26246383)
19. Calzascia T., Masson F., Di Berardino-Besson W., Contassot E., Wilmotte R., Aurrand-Lions M., Regg C., Dietrich P. Y., Walker P. R., Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs Immunity 2005 22 2 175 184 (Pubitemid 40255709)
20. Quattrocchi K. B., Miller C. H., Cush S., Bernard S. A., Dull S. T., Smith M., Gudeman S., Varia M. A., Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas Journal of Neuro-Oncology 1999 45 2 141 157 (Pubitemid 30197728)
21. Brabb T., Von Dassow P., Ordonez N., Schnabel B., Duke B., Goverman J., In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity Journal of Experimental Medicine 2000 192 6 871 880
22. Gigliotti F., Lee D., Insel R. A., Scheld W. M., IgG penetration into the cerebrospinal fluid in a rabbit model of meningitis Journal of Infectious Diseases 1987 156 2 394 398 (Pubitemid 17098210)
23. Stemmler H. J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V., Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anti-Cancer Drugs 2007 18 1 23 28 (Pubitemid 44949792)
24. Heimberger A. B., Sampson J. H., Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro-Oncology 2011 13 1 3 13
25. Rolle C. E., Sengupta S., Lesniak M. S., Challenges in clinical design of immunotherapy trials for malignant glioma Neurosurgery Clinics of North America 2010 21 1 201 214
26. El Andaloussi A., Lesniak M. S., An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme Neuro-Oncology 2006 8 3 234 243 (Pubitemid 46542648)
27. Brantley E. C., Benveniste E. N., Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas Molecular Cancer Research 2008 6 5 675 684
28. Di Tomaso T., Mazzoleni S., Wang E., Sovena G., Clavenna D., Franzin A., Mortini P., Ferrone S., Doglioni C., Marincola F. M., Galli R., Parmiani G., Maccalli C., Immunobiological characterization of cancer stem cells isolated from glioblastoma patients Clinical Cancer Research 2010 16 3 800 813
29. Jacobs J. F. M., Idema A. J., Bol K. F., Nierkens S., Grauer O. M., Wesseling P., Grotenhuis J. A., Hoogerbrugge P. M., De Vries I. J. M., Adema G. J., Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors Neuro-Oncology 2009 11 4 394 402
30. Wainwright D. A., Sengupta S., Han Y., Ulasov I. V., Lesniak M. S., The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human gliom PLoS ONE 2010 5 10, article e15390
31. Langowski J. L., Zhang X., Wu L., Mattson J. D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R. A., Oft M., IL-23 promotes tumour incidence and growth Nature 2006 442 7101 461 465 (Pubitemid 44264796)
32. Brennan C., Momota H., Hambardzumyan D., Ozawa T., Tandon A., Pedraza A., Holland E., Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations PLoS ONE 2009 4 11, article e7752
33. Harling-Berg C., Knopf P. M., Merriam J., Cserr H. F., Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid Journal of Neuroimmunology 1989 25 2-3 185 193 (Pubitemid 19276908)
34. Harling-Berg C. J., Hallett J. J., Park J. T., Knopf P. M., Hierarchy of immune responses to antigen in the normal brain Current Topics in Microbiology and Immunology 2002 265 1 22 (Pubitemid 34241976)
35. Harling-Berg C. J., Park J. T., Knopf P. M., Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation Journal of Neuroimmunology 1999 101 2 111 127 (Pubitemid 29516453)
36. Jansen T., Tyler B., Mankowski J. L., Recinos V. R., Pradilla G., Legnani F., Laterra J., Olivi A., FasL gene knock-down therapy enhances the antiglioma immune response Neuro-Oncology 2010 12 5 482 489
37. Rodrigues J. C., Gonzalez G. C., Zhang L., Ibrahim G., Kelly J. J., Gustafson M. P., Lin Y., Dietz A. B., Forsyth P. A., Yong V. W., Parney I. F., Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties Neuro-Oncology 2010 12 4 351 365
38. Dubois C. M., Laprise M. H., Blanchette F., Gentry L. E., Leduc R., Processing of transforming growth factor 1 precursor by human furin convertase Journal of Biological Chemistry 1995 270 18 10618 10624
39. Tritschler I., Gramatzki D., Capper D., Mittelbronn M., Meyermann R., Saharinen J., Wick W., Keski-Oja J., Weller M., Modulation of TGF- activity by latent TGF- -binding protein 1 in human malignant glioma cells International Journal of Cancer 2009 125 3 530 540
40. Kanzaki T., Olofsson A., Moren A., Wernstedt C., Hellman U., Miyazono K., Claesson-Welsh L., Heldin C. H., TGF- 1 binding protein: A component of the large latent complex of TGF- 1 with multiple repeat sequences Cell 1990 61 6 1051 1061
41. Annes J. P., Munger J. S., Rifkin D. B., Making sense of latent TGF activation Journal of Cell Science 2003 116, part 2 217 224 (Pubitemid 36163863)
42. Kirkbride K. C., Blobe G. C., Inhibiting the TGF- signalling pathway as a means of cancer immunotherapy Expert Opinion on Biological Therapy 2003 3 2 251 261 (Pubitemid 36458757)
43. de Martin R., Haendler B., Hofer-Warbinek R., Gaugitsch H., Wrann M., Schlsener H., Seifert J. M., Bodmer S., Fontana A., Hofer E., Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family EMBO Journal 1987 6 12 3673 3677
44. Wrann M., Bodmer S., de Martin R., Siepl C., Hofer-Warbinek R., Frei K., Hofer E., Fontana A., T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta EMBO Journal 1987 6 6 1633 1636
45. Anido J., Sez-Borderas A., Gonzlez-Junc A., Rodn L., Folch G., Carmona M. A., Prieto-Snchez R. M., Barba I., Martnez-Sez E., Prudkin L., Cuartas I., Ravents C., Martnez-Ricarte F., Poca M. A., Garca-Dorado D., Lahn M. M., Yingling J. M., Rodn J., Sahuquillo J., Baselga J., Seoane J., TGF- Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma Cancer Cell 2010 18 6 655 668
46. Pen A., Moreno M. J., Durocher Y., Deb-Rinker P., Stanimirovic D. B., Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF- signaling Oncogene 2008 27 54 6834 6844
47. Arslan F., Bosserhoff A. K., Nickl-Jockschat T., Doerfelt A., Bogdahn U., Hau P., The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor- 2 British Journal of Cancer 2007 96 10 1560 1568 (Pubitemid 46762960)
48. Tabatabai G., Frank B., Mhle R., Weller M., Wick W., Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF- -dependent HIF-1 -mediated induction of CXCL12 Brain 2006 129, part 9 2426 2435 (Pubitemid 44522127)
49. Ehrhart E. J., Segarini P., Tsang M. L. S., Carroll A. G., Barcellos-Hoff M. H., Latent transforming growth factor 1 activation in situ: quantitative and functional evidence after low-dose -irradiation FASEB Journal 1997 11 12 991 1002 (Pubitemid 27425901)
50. Garnett C. T., Palena C., Chakraborty M., Tsang K. Y., Schlom J., Hodge J. W., Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes Cancer Research 2004 64 21 7985 7994 (Pubitemid 39446933)
51. Klein B., Loven D., Lurie H., Rakowsky E., Nyska A., Levin I., Klein T., The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture Journal of Neurosurgery 1994 80 6 1074 1077 (Pubitemid 24154185)
52. Olschowka J. A., Kyrkanides S., Harvey B. K., O'Banion M. K., Williams J. P., Rubin P., Hansen J. T., ICAM-1 induction in the mouse CNS following irradiation Brain, Behavior, and Immunity 1997 11 4 273 285 (Pubitemid 28108138)
53. Jobling M. F., Mott J. D., Finnegan M. T., Jurukovski V., Erickson A. C., Walian P. J., Taylor S. E., Ledbetter S., Lawrence C. M., Rifkin D. B., Barcellos-Hoff M. H., Isoform-specific activation of latent transforming growth factor (LTGF- ) by reactive oxygen species Radiation Research 2006 166 6 839 848 (Pubitemid 44888249)
54. Wu A., Wei J., Kong L. Y., Wang Y., Priebe W., Qiao W., Sawaya R., Heimberger A. B., Glioma cancer stem cells induce immunosuppressive macrophages/microglia Neuro-Oncology 2010 12 11 1113 1125
55. Shao C., Folkard M., Prise K. M., Role of TGF- 1 and nitric oxide in the bystander response of irradiated glioma cells Oncogene 2008 27 4 434 440
56. Wick W., Platten M., Weller M., Glioma cell invasion: Regulation of metalloproteinase activity by TGF- Journal of Neuro-Oncology 2001 53 2 177 185 (Pubitemid 33034690)
57. Kim G. H., Kang S. Y., Kwak H. J., Baek K. M., Hong S. H., Lee H. J., Sohn Y. W., Transforming growth factor- 1 bioassay involving matrix metalloproteinase-2 induction Journal of Interferon and Cytokine Research 2010 30 9 667 672
58. Bogdahn U., Hau P., Stockhammer G., Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro-Oncology 2011 13 1 132 142
59. Jaschinski F., Rothhammer T., Jachimczak P., Seitz C., Schneider A., Schlingensiepen K. H., The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Current Pharmaceutical Biotechnology. In press
60. Barcellos-Hoff M. H., Newcomb E. W., Zagzag D., Narayana A., Therapeutic targets in malignant glioblastoma microenvironment Seminars in Radiation Oncology 2009 19 3 163 170
61. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., Gilboa E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity Journal of Experimental Medicine 1990 172 4 1217 1224 (Pubitemid 20343223)
62. Saris S. C., Rosenberg S. A., Friedman R. B., Rubin J. T., Barba D., Oldfield E. H., Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier Journal of Neurosurgery 1988 69 1 29 34
63. Merchant R. E., McVicar D. W., Merchant L. H., Young H. F., Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-. Results of a phase I clinical trial Journal of Neuro-Oncology 1992 12 1 75 83
64. Barba D., Saris S. C., Holder C., Rosenberg S. A., Oldfield E. H., Intratumoral LAK cell and interleukin-2 therapy of human gliomas Journal of Neurosurgery 1989 70 2 175 182 (Pubitemid 19051711)
65. Colombo F., Barzon L., Franchin E., Pacenti M., Pinna V., Danieli D., Zanusso M., Pal G., Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results Cancer Gene Therapy 2005 12 10 835 848 (Pubitemid 43086285)
66. Ewend M. G., Thompson R. C., Anderson R., Sills A. K., Staveley-O'Carroll K., Tyler B. M., Hanes J., Brat D., Thomas M., Jaffee E. M., Pardoll D. M., Brem H., Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the Central Nervous System Journal of Immunotherapy 2000 23 4 438 448 (Pubitemid 30457701)
67. Pedretti M., Verpelli C., Mrlind J., Bertani G., Sala C., Neri D., Bello L., Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma British Journal of Cancer 2010 103 6 827 836
68. Fujita M., Scheurer M. E., Decker S. A., McDonald H. A., Kohanbash G., Kastenhuber E. R., Kato H., Bondy M. L., Ohlfest J. R., Okada H., Role of type 1 IFNs in antiglioma immunosurveillance-Using mouse studies to guide examination of novel prognostic markers in humans Clinical Cancer Research 2010 16 13 3409 3419
69. Farkkila M., Jaaskelainen J., Kallio M., Blomstedt G., Raininko R., Virkkunen P., Paetau A., Sarelin H., Mantyla M., Randomised, controlled study of intratumoral recombinant -interferon treatment in newly diagnosed glioblastoma British Journal of Cancer 1994 70 1 138 141 (Pubitemid 24203641)
70. Wolff J. E. A., Wagner S., Reinert C., Gnekow A., Kortmann R. D., Khl J., Van Gool S. W., Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma Journal of Neuro-Oncology 2006 79 3 315 321 (Pubitemid 44363736)
71. Allen J., Packer R., Bleyer A., Zeltzer P., Prados M., Nirenberg A., Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors Journal of Clinical Oncology 1991 9 5 783 788
72. Fetell M. R., Housepian E. M., Oster M. W., Cote D. N., Sisti M. B., Marcus S. G., Fisher P. B., Intratumor administration of beta-interferon in recurrent malignant gliomas. A Phase I clinical and laboratory study Cancer 1990 65 1 78 83 (Pubitemid 20026814)
73. Mahaley M. S., Dropcho E. J., Bertsch L., Tirey T., Gillespie G. Y., Systemic beta-interferon therapy for recurrent gliomas: a brief report Journal of Neurosurgery 1989 71 5, part 1 639 641 (Pubitemid 19275758)
74. Wakabayashi T., Kayama T., Nishikawa R., Takahashi H., Yoshimine T., Hashimoto N., Aoki T., Kurisu K., Natsume A., Ogura M., Yoshida J., A multicenter phase I trial of interferon- and temozolomide combination therapy for high-grade gliomas (INTEGRA Study) Japanese Journal of Clinical Oncology 2008 38 10 715 718
75. Buckner J. C., Brown L. D., Kugler J. W., Cascino T. L., Krook J. E., Mailliard J. A., Kardinal C. G., Tschetter L. K., O'Fallon J. R., Scheithauer B. W., Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma Journal of Neurosurgery 1995 82 3 430 435
76. Buckner J. C., Schomberg P. J., McGinnis W. L., Cascino T. L., Scheithauer B. W., O'Fallon J. R., Morton R. F., Kuross S. A., Mailliard J. A., Hatfield A. K., Cole J. T., Steen P. D., Bernath A. M., A Phase III study of radiation therapy plus carmustine with or without recombinant interferon- in the treatment of patients with newly diagnosed high-grade glioma Cancer 2001 92 2 420 433 (Pubitemid 32664450)
77. Olson J. J., McKenzie E., Skurski-Martin M., Zhang Z., Brat D., Phuphanich S., Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme Journal of Neuro-Oncology 2008 90 3 293 299
78. Villeneuve J., Tremblay P., Vallires L., Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation Cancer Research 2005 65 9 3928 3936 (Pubitemid 40616375)
79. Benedetti S., Bruzzone M. G., Pollo B., DiMeco F., Magrassi L., Pirola B., Cirenei N., Colombo M. P., Finocchiaro G., Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene Cancer Research 1999 59 3 645 652 (Pubitemid 29076063)
80. Okada H., Lieberman F. S., Walter K. A., Lunsford L. D., Kondziolka D. S., Bejjani G. K., Hamilton R. L., Torres-Trejo A., Kalinski P., Cai Q., Mabold J. L., Edington H. D., Butterfield L. H., Whiteside T. L., Potter D. M., Schold S. C., Pollack I. F., Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas Journal of Translational Medicine 2007 5, article 67
81. Liu Y., Ehtesham M., Samoto K., Wheeler C. J., Thompson R. C., Villarreal L. P., Black K. L., Yu J. S., In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma Cancer Gene Therapy 2002 9 1 9 15 (Pubitemid 34052849)
82. Dimeco F., Rhines L. D., Hanes J., Tyler B. M., Brat D., Torchiana E., Guarnieri M., Colombo M. P., Pardoll D. M., Finocchiaro G., Brem H., Olivi A., Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats Journal of Neurosurgery 2000 92 3 419 427 (Pubitemid 30112382)
83. Ehtesham M., Kabos P., Kabosova A., Neuman T., Black K. L., Yu J. S., The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma Cancer Research 2002 62 20 5657 5663 (Pubitemid 35204717)
84. Kikuchi T., Akasaki Y., Abe T., Fukuda T., Saotome H., Ryan J. L., Kufe D. W., Ohno T., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12 Journal of Immunotherapy 2004 27 6 452 459 (Pubitemid 39447353)
85. Herrlinger U., Kramm C. M., Johnston K. M., Louis D. N., Finkelstein D., Reznikoff G., Dranoff G., Breakefield X. O., Yu J. S., Vaccination for experimental gliomas using GM-CSF-transduced glioma cells Cancer Gene Therapy 1997 4 6 345 352 (Pubitemid 127667126)
86. Butowski N., Immunostimulants for Malignant Gliomas Neurosurgery Clinics of North America 2010 21 1 53 65
87. Iwakura Y., Ishigame H., The IL-23/IL-17 axis in inflammation Journal of Clinical Investigation 2006 116 5 1218 1222
88. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H., Regulation of the IL-23 and IL-12 balance by stat3 signaling in the tumor microenvironment Cancer Cell 2009 15 2 114 123
89. Yong V. W., Marks S., The interplay between the immune and central nervous systems in neuronal injury Neurology 2010 74 supplement 1 S9 S16
90. Dillman R. O., Duma C. M., Ellis R. A., Cornforth A. N., Schiltz P. M., Sharp S. L., Depriest M. C., Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma Journal of Immunotherapy 2009 32 9 914 919
91. Jacobs S. K., Wilson D. J., Kornblith P. L., Grimm E. A., Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial Cancer Research 1986 46 4, part 2 2101 2104 (Pubitemid 16117915)
92. Lillehei K. O., Mitchell D. H., Johnson S. D., McCleary E. L., Kruse C. A., Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy Neurosurgery 1991 28 1 16 23
93. Hayes R. L., Koslow M., Hiesiger E. M., Hymes K. B., Hochster H. S., Moore E. J., Pierz D. M., Chen D. K., Budzilovich G. N., Ransohoff J., Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma Cancer 1995 76 5 840 852
94. Dillman R. O., Duma C. M., Schiltz P. M., DePriest C., Ellis R. A., Okamoto K., Beutel L. D., De Leon C., Chico S., Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma Journal of Immunotherapy 2004 27 5 398 404 (Pubitemid 39121929)
95. Itoh K., Sawamura Y., Hosokawa M., Kobayashi H., Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor Radiation MedicineMedical Imaging and Radiation Oncology 1988 6 6 276 281 (Pubitemid 19089503)
96. Yamasaki T., Kikuchi H., An experimental approach to specific adoptive immunotherapy for malignant brain tumors Archiv fur Japanische Chirurgie 1989 58 6 485 492 (Pubitemid 20325089)
97. Tsurushima H., Liu S. Q., Tuboi K., Matsumura A., Yoshii Y., Nose T., Saijo K., Ohno T., Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes Japanese Journal of Cancer Research 1999 90 5 536 545 (Pubitemid 29267708)
98. Plautz G. E., Miller D. W., Barnett G. H., T cell adoptive immunotherapy of newly diagnosed gliomas Clinical Cancer Research 2000 6 6 2209 2218 (Pubitemid 30399186)
99. Kahlon K. S., Brown C., Cooper L. J. N., Raubitschek A., Forman S. J., Jensen M. C., Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells Cancer Research 2004 64 24 9160 9166 (Pubitemid 39665531)
100. Yaghoubi S. S., Jensen M. C., Satyamurthy N., Budhiraja S., Paik D., Czernin J., Gambhir S. S., Noninvasive detection of therapeutic cytolytic T cells with 18 F-FHBG PET in a patient with glioma Nature Clinical Practice Oncology 2009 6 1 53 58
101. Ahmed N., Salsman V. S., Kew Y., HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors Clinical Cancer Research 2010 16 2 474 485
102. Hsu F. J., Benike C., Fagnoni F., Liles T. M., Czerwinski D., Taidi B., Engleman E. G., Levy R., Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nature Medicine 1996 2 1 52 58 (Pubitemid 26028073)
103. Kugler A., Stuhler G., Walden P., Zller G., Zobywalski A., Brossart P., Trefzer U., Ullrich S., Mller C. A., Becker V., Gross A. J., Hemmerlein B., Kanz L., Mller G. A., Ringert R. H., Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids Nature Medicine 2000 6 3 332 336 (Pubitemid 30148627)
104. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nature Medicine 1998 4 3 328 332 (Pubitemid 28144092)
105. Tjoa B. A., Simmons S. J., Elgamal A., Rogers M., Ragde H., Kenny G. M., Troychak M. J., Boynton A. L., Murphy G. P., Follow-up evaluation of a phase II prostate cancer vaccine trial Prostate 1999 40 2 125 129 (Pubitemid 29304703)
106. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 2 137 148 (Pubitemid 39094044)
107. Dighe A. S., Richards E., Old L. J., Schreiber R. D., Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN receptors Immunity 1994 1 6 447 456
108. Kaplan D. H., Shankaran V., Dighe A. S., Stockert E., Aguet M., Old L. J., Schreiber R. D., Demonstration of an interferon -dependent tumor surveillance system in immunocompetent mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7556 7561 (Pubitemid 28293291)
109. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 6832 1107 1111 (Pubitemid 32391043)
110. Algarra I., Cabrera T., Garrido F., The HLA crossroad in tumor immunology Human Immunology 2000 61 1 65 73 (Pubitemid 30058768)
111. Marincola F. M., Jaffee E. M., Hicklin D. J., Ferrone S., Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Advances in Immunology 2000 74 181 273
112. Wong L. H., Krauer K. G., Hatzinisiriou I., Estcourt M. J., Hersey P., Tam N. D., Edmondson S., Devenish R. J., Ralph S. J., Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3 Journal of Biological Chemistry 1997 272 45 28779 28785 (Pubitemid 27517837)
113. Verhaak R. G. W., Hoadley K. A., Purdom E., Wang V., Qi Y., Wilkerson M. D., Miller C. R., Ding L., Golub T., Mesirov J. P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B. A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H. S., Hodgson J. G., James C. D., Sarkaria J. N., Brennan C., Kahn A., Spellman P. T., Wilson R. K., Speed T. P., Gray J. W., Meyerson M., Getz G., Perou C. M., Hayes D. N., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 2010 17 1 98 110
114. Bigner S. H., Humphrey P. A., Wong A. J., Vogelstein B., Mark J., Friedman H. S., Bigner D. D., Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts Cancer Research 1990 50 24 8017 8022
115. Libermann T. A., Nusbaum H. R., Razon N., Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Nature 1985 313 5998 144 147 (Pubitemid 15192341)
116. Li G., Mitra S., Wong A. J., The epidermal growth factor variant III peptide vaccine for treatment of malignant gsliomas Neurosurgery Clinics of North America 2010 21 1 87 93
117. Fernandes H., Cohen S., Bishayee S., Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/EGFR) expressed in cancer cells Journal of Biological Chemistry 2001 276 7 5375 5383
118. Humphrey P. A., Wong A. J., Vogelstein B., Zalutsky M. R., Fuller G. N., Archer G. E., Friedman H. S., Kwatra M. M., Bigner S. H., Bigner D. D., Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma Proceedings of the National Academy of Sciences of the United States of America 1990 87 11 4207 4211
119. Wikstrand C. J., Hale L. P., Batra S. K., Hill M. L., Humphrey P. A., Kurpad S. N., McLendon R. E., Moscatello D., Pegram C. N., Reist C. J., Traweek S. T., Wong A. J., Zalutsky M. R., Bigner D. D., Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas Cancer Research 1995 55 14 3140 3148
120. Purev E., Cai D., Miller E., Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R) The Journal of Immunology 2004 173 10 6472 6480 (Pubitemid 39487809)
121. Sampson J. H., Archer G. E., Mitchell D. A., Heimberger A. B., Bigner D. D., Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma Seminars in Immunology 2008 20 5 267 275
122. Ciesielski M. J., Kazim A. L., Barth R. F., Fenstermaker R. A., Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model Cancer Immunology, Immunotherapy 2005 54 2 107 119 (Pubitemid 40100833)
123. Harris J. R., Markl J., Keyhole limpet hemocyanin (KLH): a biomedical review Micron 1999 30 6 597 623 (Pubitemid 29492383)
124. Heimberger A. B., Crotty L. E., Archer G. E., Hess K. R., Wikstrand C. J., Friedman A. H., Friedman H. S., Bigner D. D., Sampson J. H., Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors Clinical Cancer Research 2003 9 11 4247 4254 (Pubitemid 37204046)
125. Moscatello D. K., Ramirez G., Wong A. J., A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors Cancer Research 1997 57 8 1419 1424 (Pubitemid 27175553)
126. Westphal M., Hilt D. C., Bortey E., Delavault P., Olivares R., Warnke P. C., Whittle I. R., Jaskelinen J., Ram Z., A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-Oncology 2003 5 2 79 88 (Pubitemid 36422560)
127. Heimberger A., Tumor-specific peptide vaccination in newly-diagnosed patients with GBM Journal of Clinical Oncology 2006 24 2275 2282
128. Emens L. A., Reilly R. T., Jaffee E. M., Cancer vaccines in combination with multimodality therapy Cancer Treatment and Research 2005 123 227 245
129. Debinski W., Gibo D. M., Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen Molecular Medicine 2000 6 5 440 449
130. Eguchi J., Hatano M., Nishimura F., Zhu X., Dusak J. E., Sato H., Pollack I. F., Storkus W. J., Okada H., Identification of interleukin-13 receptor 2 peptide analogues capable of inducing improved antiglioma CTL responses Cancer Research 2006 66 11 5883 5891 (Pubitemid 43927143)
131. Jarboe J. S., Johnson K. R., Choi Y., Lonser R. R., Park J. K., Expression of interleukin-13 receptor 2 in glioblastoma multiforme: implications for targeted therapies Cancer Research 2007 67 17 7983 7986 (Pubitemid 47395129)
132. Okano F., Storkus W. J., Chambers W. H., Pollack I. F., Okada H., Identification of a novel HLA-A0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor 2 chain Clinical Cancer Research 2002 8 9 2851 2855 (Pubitemid 35025729)
133. Kawakami M., Leland P., Kawakami K., Puri R. K., Mutation and functional analysis of IL-13 receptors in human malignant glioma cells Oncology Research 2001 12 11-12 459 467
134. Debinski W., Obiri N. I., Pastan I., Puri R. K., A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4 Journal of Biological Chemistry 1995 270 28 16775 16780
135. Husain S. R., Joshi B. H., Puri R. K., Interleukin-13 receptor as a unique target for anti-glioblastoma therapy International Journal of Cancer 2001 92 2 168 175 (Pubitemid 32225365)
136. Husain S. R., Puri R. K., Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS- Kaposi's sarcoma xenograft Blood 2000 95 11 3506 3513 (Pubitemid 30428484)
137. Kawakami K., Kawakami M., Joshi B. H., Puri R. K., Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer Cancer Research 2001 61 16 6194 6200 (Pubitemid 32762557)
138. Maini A., Hillman G., Haas G. P., Wang C. Y., Montecillo E., Hamzavi F., Edson Pontes J., Leland P., Pastan I., Debinski W., Puri R. K., Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of pseudomonas exotoxin Journal of Urology 1997 158 3, part 1 948 953
139. Kawakami K., Kioi M., Liu Q., Kawakami M., Puri R. K., Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy Journal of Immunotherapy 2005 28 3 193 202 (Pubitemid 40593984)
140. Brem H., Piantadosi S., Burger P. C., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 1995 345 8956 1008 1012
141. Kunwar S., Chang S. M., Prados M. D., Berger M. S., Sampson J. H., Croteau D., Sherman J. W., Grahn A. Y., Shu V. S., Dul J. L., Husain S. R., Joshi B. H., Pedain C., Puri R. K., Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies Neurosurgical Focus 2006 20 4 E15
142. Rand R. W., Kreitman R. J., Patronas N., Varricchio F., Pastan I., Puri R. K., Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma Clinical Cancer Research 2000 6 6 2157 2165 (Pubitemid 30399180)
143. Blancher A., Roubinet F., Grancher A. S., Tremoulet M., Bonate A., Delisle M. B., Calot J. P., Pourreau C., Franks C., Ducos J., Rascol A., Clanet M., Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells European Cytokine Network 1993 4 5 331 341 (Pubitemid 24001545)
144. Boiardi A., Silvani A., Ruffini P. A., Rivoltini L., Parmiani G., Broggi G., Salmaggi A., Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients Cancer Immunology Immunotherapy 1994 39 3 193 197 (Pubitemid 24298394)
145. Hayes R. L., Arbit E., Odaimi M., Pannullo S., Scheff R., Kravchinskiy D., Zaroulis C., Adoptive cellular immunotherapy for the treatment of malignant gliomas Critical Reviews in Oncology/Hematology 2001 39 1-2 31 42 (Pubitemid 32551987)
146. Jeffes E. W. B., Beamer Y. B., Jacques S., Silberman R. S., Vayuvegula B., Gupta S., Coss J. S., Yamamoto R. S., Granger G. A., Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA Journal of Neuro-Oncology 1993 15 2 141 155 (Pubitemid 23136029)
147. Sankhla S. K., Nadkarni J. S., Bhagwati S. N., Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors Journal of Neuro-Oncology 1996 27 2 133 140
148. Holladay F. P., Heitz-Turner T., Bayer W. L., Wood G. W., Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma Journal of Neuro-Oncology 1996 27 2 179 189 (Pubitemid 26052654)
149. Kitahara T., Watanabe O., Yamaura A., Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor Journal of Neuro-Oncology 1987 4 4 329 336 (Pubitemid 17037579)
150. Kruse C. A., Cepeda L., Owens B., Johnson S. D., Stears J., Lillehei K. O., Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 Cancer Immunology Immunotherapy 1997 45 2 77 87 (Pubitemid 27497682)
151. Plautz G. E., Barnett G. H., Miller D. W., Cohen B. H., Prayson R. A., Krauss J. C., Luciano M., Kangisser D. B., Shu S., Systemic T cell adoptive immunotherapy of malignant gliomas Journal of Neurosurgery 1998 89 1 42 51 (Pubitemid 28285921)
152. Sloan A. E., Dansey R., Zamorano L., Barger G., Hamm C., Diaz F., Baynes R., Wood G., Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes Neurosurgical Focus 2000 9 6, article e9
153. Tsuboi K., Saijo K., Ishikawa E., Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas Clinical Cancer Research 2003 9 9 3294 3302 (Pubitemid 37082723)
154. Wood G. W., Holladay F. P., Turner T., Wang Y. Y., Chiga M., A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma Journal of Neuro-Oncology 2000 48 2 113 120
155. Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Riedinger M. S., Zhang W., Prins R. M., Black K. L., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Research 2001 61 3 842 847 (Pubitemid 32175145)
156. Liau L. M., Prins R. M., Kiertscher S. M., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment Clinical Cancer Research 2005 11 15 5515 5525 (Pubitemid 41060828)
157. Sampson J. H., Heimberger A. B., Archer G. E., Aldape K. D., Friedman A. H., Friedman H. S., Gilbert M. R., Herndon J. E., McLendon R. E., Mitchell D. A., Reardon D. A., Sawaya R., Schmittling R. J., Shi W., Vredenburgh J. J., Bigner D. D., Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma Journal of Clinical Oncology 2010 28 31 4722 4729
158. Ardon H., De Vleeschouwer S., Van Calenbergh F., Claes L., Kramm C. M., Rutkowski S., Wolff J. E. A., Van Gool S. W., Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours Pediatric Blood and Cancer 2010 54 4 519 525
159. Caruso D. A., Orme L. M., Amor G. M., Neale A. M., Radcliff F. J., Downie P., Tang M. L. K., Ashley D. M., Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma Cancer 2005 103 6 1280 1291 (Pubitemid 40328101)
160. De Vleeschouwer S., Fieuws S., Rutkowski S., Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme Clinical Cancer Research 2008 14 10 3098 3104
161. De Vleeschouwer S., Van Calenbergh F., Demaerel P., Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report Journal of Neurosurgery 2004 100 supplement 5 492 497 (Pubitemid 38541867)
162. Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., Ohno T., Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells Cancer Immunology, Immunotherapy 2001 50 7 337 344 (Pubitemid 32835343)
163. Liau L. M., Black K. L., Martin N. A., Sykes S. N., Bronstein J. M., Jouben-Steele L., Mischel P. S., Belldegrun A., Cloughesy T. F., Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report Neurosurgical Focus 2000 9 6, article e8
164. Rosenberg S. A., Yang J. C., Restifo N. P., Cancer immunotherapy: moving beyond current vaccines Nature Medicine 2004 10 9 909 915 (Pubitemid 39273730)
165. Rutkowski S., De Vleeschouwer S., Kaempgen E., Wolff J. E. A., Khl J., Demaerel P., Warmuth-Metz M., Flamen P., Van Calenbergh F., Plets C., Srensen N., Opitz A., Van Gool S. W., Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study British Journal of Cancer 2004 91 9 1656 1662 (Pubitemid 39546137)
166. Sampson J. H., Archer G. E., Mitchell D. A., Heimberger A. B., Herndon J. E., Lally-Goss D., McGehee-Norman S., Paolino A., Reardon D. A., Friedman A. H., Friedman H. S., Bigner D. D., An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme Molecular Cancer Therapeutics 2009 8 10 2773 2779
167. Walker D. G., Laherty R., Tomlinson F. H., Chuah T., Schmidt C., Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy Journal of Clinical Neuroscience 2008 15 2 114 121 (Pubitemid 50017630)
168. Wen P. Y., Macdonald D. R., Reardon D. A., Cloughesy T. F., Sorensen A. G., Galanis E., Degroot J., Wick W., Gilbert M. R., Lassman A. B., Tsien C., Mikkelsen T., Wong E. T., Chamberlain M. C., Stupp R., Lamborn K. R., Vogelbaum M. A., van den Bent M. J., Chang S. M., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group Journal of Clinical Oncology 2010 28 11 1963 1972
169. Wheeler C. J., Black K. L., Liu G., Mazer M., Zhang X. X., Pepkowitz S., Goldfinger D., Ng H., Irvin D., Yu J. S., Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients Cancer Research 2008 68 14 5955 5964
170. Wheeler C. J., Das A., Liu G., Yu J. S., Black K. L., Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination Clinical Cancer Research 2004 10 16 5316 5326 (Pubitemid 39100466)
171. Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., Tanaka R., Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial British Journal of Cancer 2003 89 7 1172 1179 (Pubitemid 37363398)
172. Yamanaka R., Homma J., Yajima N., Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial Clinical Cancer Research 2005 11 11 4160 4167 (Pubitemid 40791581)
173. Yu J. S., Liu G., Ying H., Yong W. H., Black K. L., Wheeler C. J., Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Research 2004 64 14 4973 4979 (Pubitemid 38924545)
174. Schneider T., Gerhards R., Kirches E., Firsching R., Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme Journal of Neuro-Oncology 2001 53 1 39 46 (Pubitemid 32936658)
175. Steiner H. H., Bonsanto M. M., Beckhove P., Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit Journal of Clinical Oncology 2004 22 21 4272 4281 (Pubitemid 41185148)
176. Ishikawa E., Tsuboi K., Yamamoto T., Muroi A., Takano S., Enomoto T., Matsumura A., Ohno T., Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients Cancer Science 2007 98 8 1226 1233 (Pubitemid 46993543)
177. Parsa A., Crane C., Wilson S., Autologous tumor derived gp96 evokes a tumor specific immune response in recurrent glioma patients that correlates with clinical response to therapy Proceedings of the AACE-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 2007
178. Husain S. R., Behari N., Kreitman R. J., Pastan I., Puri R. K., Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy Cancer Research 1998 58 16 3649 3653 (Pubitemid 28376564)
179. Joshi B. H., Leland P., Asher A., Prayson R. A., Varricchio F., Puri R. K., In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures Cancer Research 2001 61 22 8058 8061 (Pubitemid 33091589)
180. Kawakami K., Leland P., Puri R. K., Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells Cancer Research 2000 60 11 2981 2987 (Pubitemid 30395824)
181. Puri R. K., Leland P., Kreitman R. J., Pastan I., Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein International Journal of Cancer 1994 58 4 574 581 (Pubitemid 24268102)
182. Murata T., Noguchi P. D., Puri R. K., Receptors for interleukin (IL)-4 do not associate with the common chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells Journal of Biological Chemistry 1995 270 51 30829 30836 (Pubitemid 26005154)
183. Murata T., Obiri N. I., Puri R. K., Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review) International Journal of Molecular Medicine 1998 1 3 551 557
184. Murata T., Taguchi J., Puri R. K., Interleukin-13 receptor ' but not chain: A functional component of interleukin-4 receptors Blood 1998 91 10 3884 3891 (Pubitemid 28225757)
185. Debinski W., Puri R. K., Kreitman R. J., Pastan I., A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin Journal of Biological Chemistry 1993 268 19 14065 14070 (Pubitemid 23195524)
186. Joshi B. H., Leland P., Silber J., Kreitman R. J., Pastan I., Berger M., Puri R. K., IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein British Journal of Cancer 2002 86 2 285 291 (Pubitemid 34185160)
187. Kawakami M., Kawakami K., Puri R. K., Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy Journal of Neuro-Oncology 2003 65 1 15 25 (Pubitemid 37441311)
188. Lampson L. A., Wen P., Roman V. A., Morris J. H., Sarid J. A., Disseminating tumor cells and their interactions with leukocytes visualized in the brain Cancer Research 1992 52 4 1018 1025
189. Satoh J., Lee Y. B., Kim S. U., T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture Brain Research 1995 704 1 92 96
190. Wheeler C. J., Black K. L., DCVax-Brain and DC vaccines in the treatment of GBM Expert Opinion on Investigational Drugs 2009 18 4 509 519
191. Jger E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A., Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo International Journal of Cancer 1996 66 4 470 476 (Pubitemid 26178170)
192. Parajuli P., Mathupala S., Sloan A. E., Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: In vitro induction of cytolytic and natural killer-like T cells Neurosurgery 2004 55 5 1194 1203 (Pubitemid 39525225)
193. Mahaley M. S., Bigner D. D., Dudka L. F., Immunobiology of primary intracranial tumorspart 7: active immunization of patients with anaplastic human glioma cells: a pilot study Journal of Neurosurgery 1983 59 2 201 207 (Pubitemid 13029196)
194. Wikstrand C. J., Bigner D. D., Immunobiologic aspects of the brain and human gliomas. A review American Journal of Pathology 1980 98 2 515 567 (Pubitemid 10154807)
195. Yang I., Han S., Parsa A. T., Heat-shock protein vaccines as active immunotherapy against human gliomas Expert Review of Anticancer Therapy 2009 9 11 1577 1582
196. Binder R. J., Heat shock protein vaccines: From bench to bedside International Reviews of Immunology 2006 25 5-6 353 375 (Pubitemid 44972271)
197. Srivastava P. K., Amato R. J., Heat shock proteins: the Swiss Army Knife vaccines against cancers and infectious agents Vaccine 2001 19 1719 2590 2597 (Pubitemid 32234277)
198. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M. R., Gallino G., Piris A., Cattelan A., Lazzari I., Carrabba M., Scita G., Santantonio C., Pilla L., Tragni G., Lombardo C., Arienti F., Marchian A., Queirolo P., Bertolini F., Cova A., Lamaj E., Ascani L., Camerini R., Corsi M., Cascinelli N., Lewis J. J., Srivastava P., Parmiani G., Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings Journal of Clinical Oncology 2002 20 20 4169 4180 (Pubitemid 35191019)
199. Li Z., Qiao Y., Liu B., Laska E. J., Chakravarthi P., Kulko J. M., Bona R. D., Fang M., Hegde U., Moyo V., Tannenbaum S. H., Ménoret A., Gaffney J., Glynn L., Runowicz C. D., Srivastava P. K., Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia Clinical Cancer Research 2005 11 12 4460 4468 (Pubitemid 40825636)
200. Mazzaferro V., Coppa J., Carrabba M. G., Rivoltini L., Schiavo M., Regalia E., Mariani L., Camerini T., Marchian A., Andreola S., Camerini R., Corsi M., Lewis J. J., Srivastava P. K., Parmiani G., Vaccination with autologous tumor-derived heat-shock protein Gp96 after liver resection for metastatic colorectal cancer Clinical Cancer Research 2003 9 9 3235 3245 (Pubitemid 37082717)
201. Rivoltini L., Castelli C., Carrabba M., Mazzaferro V., Pilla L., Huber V., Coppa J., Gallino G., Scheibenbogen C., Squarcina P., Cova A., Camerini R., Lewis J. J., Srivastava P. K., Parmiani G., Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells Journal of Immunology 2003 171 7 3467 3474 (Pubitemid 37254548)
202. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E. A., Stassi G., Larocca L. M., De Maria R., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells Nature 2010 468 7325 824 830
203. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K. E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V., Glioblastoma stem-like cells give rise to tumour endothelium Nature 2010 468 7325 829 833
204. Mannino M., Chalmers A. J., Radioresistance of glioma stem cells: intrinsic characteristic or property of the microenvironment-stem cell unit? Molecular Oncology 2011 5 4 374 386
205. Tamura K., Aoyagi M., Wakimoto H., Ando N., Nariai T., Yamamoto M., Ohno K., Accumulation of CD133-positive glioma cells after high-dose irradiation by gamma knife surgery plus external beam radiation: clinical article Journal of Neurosurgery 2010 113 2 310 318
206. McCord A. M., Jamal M., Williams E. S., Camphausen K., Tofilon P. J., CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines Clinical Cancer Research 2009 15 16 5145 5153
207. Calabrese C., Poppleton H., Kocak M., Hogg T. L., Fuller C., Hamner B., Oh E. Y., Gaber M. W., Finklestein D., Allen M., Frank A., Bayazitov I. T., Zakharenko S. S., Gajjar A., Davidoff A., Gilbertson R. J., A perivascular niche for brain tumor stem cells Cancer Cell 2007 11 1 69 82 (Pubitemid 46054518)
208. Soeda A., Park M., Lee D., Mintz A., Androutsellis-Theotokis A., McKay R. D., Engh J., Iwama T., Kunisada T., Kassam A. B., Pollack I. F., Park D. M., Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 Oncogene 2009 28 45 3949 3959
209. Bodmer S., Strommer K., Frei K., Siepl C., De Tribolet N., Heid I., Fontana A., Immunosuppression and transforming growth factor- in glioblastoma. Preferential production of transforming growth factor- 2 Journal of Immunology 1989 143 10 3222 3229 (Pubitemid 20010149)
210. Qiu B., Zhang D., Wang C., Tao J., Tie X., Qiao Y., Xu K., Wang Y., Wu A., IL-10 and TGF- 2 are overexpressed in tumor spheres cultured from human gliomas Molecular Biology Reports 2011 38 5 3585 3591
211. Lottaz C., Beier D., Meyer K., Kumar P., Hermann A., Schwarz J., Junker M., Oefner P. J., Bogdahn U., Wischhusen J., Spang R., Storch A., Beier C. P., Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin Cancer Research 2010 70 5 2030 2040
212. Avril T., Saikali S., Vauleon E., Jary A., Hamlat A., De Tayrac M., Mosser J., Quillien V., Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions Journal of Neuroimmunology 2010 225 1-2 22 33
213. Yu H., Pardoll D., Jove R., STATs in cancer inflammation and immunity: a leading role for STAT3 Nature Reviews Cancer 2009 9 11 798 809
214. Darnell J. E., Kerr I. M., Stark G. R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 1994 264 5164 1415 1421 (Pubitemid 24217131)
215. Darnell J. E. Jr., STATs and gene regulation Science 1997 277 5332 1630 1635 (Pubitemid 27446219)
216. Gariboldi M. B., Ravizza R., Monti E., The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells Biochemical Pharmacology 2010 80 4 455 462
217. Stahl N., Farruggella T. J., Boulton T. G., Zhong Z., Darnell J. E. Jr., Yancopoulos G. D., Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors Science 1995 267 5202 1349 1353
218. Wen Z., Zhong Z., Darnell J. E. Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation Cell 1995 82 2 241 250
219. Zhong Z., Wen Z., Darnell J. E. Jr., Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science 1994 264 5155 95 98 (Pubitemid 24144493)
220. Turkson J., Jove R., STAT proteins: Novel molecular targets for cancer drug discovery Oncogene 2000 19 56 6613 6626 (Pubitemid 32197700)
221. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., Hess K., Conrad C., Madden T., Sawaya R., Kondo S., Priebe W., Kondo Y., A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo Oncogene 2007 26 17 2435 2444 (Pubitemid 46597261)
222. Birner P., Toumangelova-Uzeir K., Natchev S., Guentchev M., STAT3 tyrosine phosphorylation influences survival in glioblastoma Journal of Neuro-Oncology 2010 100 3 339 343
223. Kang S. H., Yu M. O., Park K. J., Chi S. G., Park D. H., Chung Y. G., Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma Neurosurgery 2010 67 5 1386 1395
224. Chen F., Xu Y., Luo Y., Zheng D., Song Y., Yu K., Li H., Zhang L., Zhong W., Ji Y., Down-regulation of stat3 decreases invasion activity and induces apoptosis of human glioma cells Journal of Molecular Neuroscience 2010 40 3 353 359
225. Sherry M. M., Reeves A., Wu J. K., Cochran B. H., STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells Stem Cells 2009 27 10 2383 2392
226. Villalva C., Martin-Lannerée S., Cortes U., Dkhissi F., Wager M., Le Corf A., Tourani J. M., Dusanter-Fourt I., Turhan A. G., Karayan-Tapon L., STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? International Journal of Cancer 2011 128 4 826 838
227. Zhang L., Alizadeh D., van Handel M., Kortylewski M., Yu H., Badie B., Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice Glia 2009 57 13 1458 1467
228. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mulé J., Kerr W. G., Jove R., Pardoll D., Yu H., Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity Nature Medicine 2005 11 12 1314 1321 (Pubitemid 41752912)
229. Wei J., Wu A., Kong L. Y., Hypoxia potentiates glioma-mediated immunosuppression PLoS One 2011 6 1, article e16195
230. De La Iglesia N., Konopka G., Puram S. V., Chan J. A., Bachoo R. M., You M. J., Levy D. E., DePinho R. A., Bonni A., Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway Genes and Development 2008 22 4 449 462 (Pubitemid 351272753)
231. Aberg M. A., Ryttsen F., Hellgren G., Selective introduction of antisense oligonucleotides into single adult CNS progenitor cells using electroporation demonstrates the requirement of STAT3 activation for CNTF-induced gliogenesis Molecular and Cellular Neuroscience 2001 17 3 426 443 (Pubitemid 32289847)
232. Bonni A., Sun Y., Nadal-Vicens M., Bhatt A., Frank D. A., Rozovsky I., Stahl N., Yancopoulos G. D., Greenberg M. E., Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway Science 1997 278 5337 477 483 (Pubitemid 27454434)
233. De La Iglesia N., Puram S. V., Bonni A., STAT3 regulation of glioblastoma pathogenesis Current Molecular Medicine 2009 9 5 580 590
234. Lo H. W., Hsu S. C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J. Y., Hung M. C., Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway Cancer Cell 2005 7 6 575 589 (Pubitemid 40799250)
235. Gao L., Li F., Dong B., Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells International Journal of Radiation Oncology Biology Physics 2010 77 4 1223 1231
236. Rahaman S. O., Harbor P. C., Chernova O., Barnett G. H., Vogelbaum M. A., Haque S. J., Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells Oncogene 2002 21 55 8404 8413 (Pubitemid 36054883)
237. Xiong H., Du W., Zhang Y. J., Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Molecular Carcinogenesis. In press
238. Wei J., Barr J., Kong L. Y., Wang Y., Wu A., Sharma A. K., Gumin J., Henry V., Colman H., Priebe W., Sawaya R., Lang F. F., Heimberger A. B., Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway Molecular Cancer Therapeutics 2010 9 1 67 78
239. Dittmer U., He H., Messer R. J., Schimmer S., Olbrich A. R. M., Ohlen C., Greenberg P. D., Stromnes I. M., Iwashiro M., Sakaguchi S., Evans L. H., Peterson K. E., Yang G., Hasenkrug K. J., Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection Immunity 2004 20 3 293 303 (Pubitemid 38388231)
240. Misra N., Bayry J., Lacroix-Desmazes S., Kazatchkine M. D., Kaveri S. V., Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells Journal of Immunology 2004 172 8 4676 4680 (Pubitemid 38456386)
241. Ralainirina N., Poli A., Michel T., Poos L., Andrs E., Hentges F., Zimmer J., Control of NK cell functions by CD4+CD25+ regulatory T cells Journal of Leukocyte Biology 2007 81 1 144 153 (Pubitemid 46021263)
242. Zhao D. M., Thornton A. M., DiPaolo R. J., Shevach E. M., Activated CD4+CD25+ T cells selectively kill B lymphocytes Blood 2006 107 10 3925 3932 (Pubitemid 43726798)
243. Taams L. S., Van Amelsfort J. M. R., Tiemessen M. M., Jacobs K. M. G., De Jong E. C., Akbar A. N., Bijlsma J. W. J., Lafeber F. P. J. G., Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells Human Immunology 2005 66 3 222 230 (Pubitemid 40395242)
244. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A. H., Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood Journal of Experimental Medicine 2001 193 11 1285 1294 (Pubitemid 32524778)
245. Cosmi L., Liotta F., Angeli R., Mazzinghi B., Santarlasci V., Manetti R., Lasagni L., Vanini V., Romagnani P., Maggi E., Annunziato F., Romagnani S., Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines Blood 2004 103 8 3117 3121 (Pubitemid 38451689)
246. Jordan J. T., Sun W., Hussain S. F., DeAngulo G., Prabhu S. S., Heimberger A. B., Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy Cancer Immunology, Immunotherapy 2008 57 1 123 131 (Pubitemid 350043644)
247. Heimberger A. B., Abou-Ghazal M., Reina-Ortiz C., Yang D. S., Sun W., Qiao W., Hiraoka N., Fuller G. N., Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas Clinical Cancer Research 2008 14 16 5166 5172
248. Kong L. Y., Abou-Ghazal M. K., Wei J., Chakraborty A., Sun W., Qiao W., Fuller G. N., Fokt I., Grimm E. A., Schmittling R. J., Archer G. E., Sampson J. H., Priebe W., Heimberger A. B., A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells Clinical Cancer Research 2008 14 18 5759 5768
249. Fecci P. E., Ochiai H., Mitchell D. A., Grossi P. M., Sweeney A. E., Archer G. E., Cummings T., Allison J. P., Bigner D. D., Sampson J. H., Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4 + T cell compartment without affecting regulatory T-cell function Clinical Cancer Research 2007 13 7 2158 2167 (Pubitemid 46649886)
250. Read S., Malmstrm V., Powrie F., Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation Journal of Experimental Medicine 2000 192 2 295 302 (Pubitemid 30470312)
251. Sutmuller R. P. M., Van Duivenvoorde L. M., Van Elsas A., Schumacher T. N. M., Wildenberg M. E., Allison J. P., Toes R. E. M., Offringa R., Melief C. J. M., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses Journal of Experimental Medicine 2001 194 6 823 832 (Pubitemid 32983017)
252. Fecci P. E., Sweeney A. E., Grossi P. M., Nair S. K., Learn C. A., Mitchell D. A., Cui X., Cummings T. J., Bigner D. D., Gilboa E., Sampson J. H., Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells Clinical Cancer Research 2006 12 14, part 1 4294 4305
253. Humphries W., Wei J., Sampson J. H., Heimberger A. B., The role of tregs in glioma-mediated immunosuppression: potential target for intervention Neurosurgery Clinics of North America 2010 21 1 125 137
254. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Ménard C., Ghiringhelli F., Terme M., Carpentier A. F., Darrasse-Jse G., Lemonnier F., Zitvogel L., Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines Journal of Immunology 2006 176 5 2722 2729
255. Holtl L., Ramoner R., Zelle-Rieser C., Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide Cancer Immunology, Immunotherapy 2005 54 7 663 670 (Pubitemid 40884162)
256. MacLean G. D., Miles D. W., Rubens R. D., Reddish M. A., Longenecker B. M., Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide Journal of Immunotherapy With Emphasis on Tumor Immunology 1996 19 4 309 316 (Pubitemid 26313521)
257. Brooks W. H., Markesbery W. R., Gupta G. D., Roszman T. L., Relationship of lymphocyte invasion and survival of brain tumor patients Annals of Neurology 1978 4 3 219 224 (Pubitemid 8389815)
258. Safdari Gh. H. H., Hochberg F. H., Richardson E. P. Jr., Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas Surgical Neurology 1985 23 3 221 226 (Pubitemid 15138393)
259. Strik H. M., Stoll M., Meyermann R., Immune cell infiltration of intrinsic and metastatic intracranial tumours Anticancer Research 2004 24 1 37 42 (Pubitemid 38279686)
260. Jacobs J. F. M., Idema A. J., Bol K. F., Grotenhuis J. A., de Vries I. J. M., Wesseling P., Adema G. J., Prognostic significance and mechanism of Treg infiltration in human brain tumors Journal of Neuroimmunology 2010 225 1-2 195 199